Reviewing Vericel Corporation (VCEL) & Its Competitors
Vericel Corporation (NASDAQ: VCEL) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it compare to its rivals? We will compare Vericel Corporation to related companies based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, risk, dividends and valuation.
Risk and Volatility
Vericel Corporation has a beta of 3.17, suggesting that its stock price is 217% more volatile than the S&P 500. Comparatively, Vericel Corporation’s rivals have a beta of 1.28, suggesting that their average stock price is 28% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Vericel Corporation and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Vericel Corporation Competitors||113||748||1608||58||2.64|
Vericel Corporation presently has a consensus price target of $6.33, indicating a potential upside of 6.00%. As a group, “Biopharmaceuticals” companies have a potential upside of 7.80%. Given Vericel Corporation’s rivals higher probable upside, analysts clearly believe Vericel Corporation has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares Vericel Corporation and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Vericel Corporation||$53.77 million||-$20.03 million||-5.43|
|Vericel Corporation Competitors||$579.30 million||$241.72 million||-6.60|
Vericel Corporation’s rivals have higher revenue and earnings than Vericel Corporation. Vericel Corporation is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
33.8% of Vericel Corporation shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 3.3% of Vericel Corporation shares are held by insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Vericel Corporation and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Vericel Corporation Competitors||-13,410.58%||245.04%||-20.96%|
Vericel Corporation rivals beat Vericel Corporation on 8 of the 12 factors compared.
Vericel Corporation Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.
Receive News & Stock Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related stocks with our FREE daily email newsletter.